Video

Audience Q&A: Best Practices in Managing HER2-Amplified CRC

Author(s):

Tanios Bekaii-Saab, MD, FACP, Mayo ClinicCathy Eng, MD, Vanderbilt University

Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.

Related Videos
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
Muhamed Baljevic, MD, FACP
Carrie L. Kitko, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Amin Nassar, MD
Sattva S. Neelapu, MD
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Related Content
Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Sanjal Desai, MD, medical oncologist, Mayo Clinic; assistant professor, medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota
May 28th 2024

Desai Details Efforts Exploring Treatment Strategies in CLL Post–BTK Inhibitor Progression

Matthew Lunning, DO, FACP, associate professor, Division of Oncology & Hematology, associate vice chair, research, Department of Internal Medicine, assistant vice chancellor, clinical research, University of Nebraska Medical Center; Sarah Rutherford, MD, assistant professor, medicine, Division of Hematology/Oncology, Weill Cornell Medicine
April 18th 2024

Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma

Muhamed Baljevic, MD, FACP
May 25th 2024

First-Line Quadruplet Regimens Continue to Enhance Outcomes in Myeloma

FDA
May 24th 2024

FDA Advisory Committee Recommends Approval of Shield Blood Test for CRC Detection in Average-Risk Adults